Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
41

Recommended

It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.

Erin Lash, CFA | 15 February 2026

The global search for a new CEO is over, ending investor concern about leadership uncertainty.

Johannes Faul, CFA | 15 February 2026

Investors were pleased with results but our fair value estimate is unchanged.

Nathan Zaia | 15 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,163.80	5.80	-0.06%
CAC 40	8,316.50	4.76	0.06%
DAX 40	24,800.91	113.97	-0.46%
Dow JONES (US)	49,500.93	48.95	0.10%
FTSE 100	10,473.69	27.34	0.26%
HKSE	26,705.94	138.82	0.52%
NASDAQ	22,546.67	50.48	-0.22%
Nikkei 225	56,806.41	135.56	-0.24%
NZX 50 Index	13,117.91	80.27	-0.61%
S&P 500	6,836.17	3.41	0.05%
S&P/ASX 200	8,937.10	8.30	-0.09%
SSE Composite Index	4,082.07	51.95	-1.26%